RxDoctor Payments Data

Katherine Gresham

Family · Jacksboro, TNNPI 1225652720

Payments from drug & device makers

$13,690in general payments, 2019–2025

Across 903 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$950
  • Lilly USA, LLC$933
  • GSK$893
  • Pfizer$728
  • Otsuka America Pharmaceutical, Inc.$718
  • plus $7K from 46 others

What the payments were for

  • Food & beverage$13,58999%
  • Education$1011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,690 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$21,983
Medicare patients
108
Services billed
485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide70$85,469
OzempicSemaglutide32$32,694
EliquisApixaban28$18,198
Spiriva RespimatTiotropium Bromide19$14,883
JardianceEmpagliflozin17$14,718
BelsomraSuvorexant13$5,482
VyvanseLisdexamfetamine Dimesylate12$4,773
Gabapentin202$3,137
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen119$2,861
Esomeprazole Magnesium17$1,971
Omeprazole105$1,516
Novolog FlexpenInsulin Aspart11$1,472
Atorvastatin Calcium125$1,207
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen32$1,146
Trazodone Hcl111$1,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$933$85,46970 claims
Novo NordiskOzempic$950$32,69432 claims
Boehringer IngelheimSpiriva Respimat, Jardiance$230$29,60136 claims
PfizerEliquis$728$18,19828 claims
MerckBelsomra$86$5,48213 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$247$4,77312 claims
Almatica Pharma LLCSertraline Hcl$17$45624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Jacksboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →